Abstract:Muscle-specific kinase (MuSK) Myasthenia Gravis (MG) represents a prototypical antibody-mediated disease characterized by predominantly focal muscle weakness (neck, facial, and bulbar muscles) and fatigability. The pathogenic antibodies mostly belong to the immunoglobulin subclass (Ig)G4, a feature which attributes them their specific properties and pathogenic profile. On the other hand, acetylcholine receptor (AChR) MG, the most prevalent form of MG, is characterized by immunoglobulin (Ig)G1 and IgG3 antibodies to the AChR. IgG4 class autoantibodies are impotent to fix complement and only weakly bind Fc-receptors expressed on immune cells and exert their pathogenicity via interfering with the interaction between their targets and binding partners (e.g. between MuSK and LRP4). Cardinal differences between AChR and MuSK-MG are the thymus involvement (not prominent in MuSK-MG), the distinct HLA alleles, and core immunopathological patterns of pathology in neuromuscular junction, structure, and function. In MuSK-MG, classical treatment options are usually less effective (e.g. IVIG) with the need for prolonged and high doses of steroids difficult to be tapered to control symptoms. Exceptional clinical response to plasmapheresis and rituximab has been particularly observed in these patients. Reduction of antibody titers follows the clinical efficacy of anti-CD20 therapies, a feature implying the role of short-lived plasma cells (SLPB) in autoantibody production. Novel therapeutic monoclonal against B cells at different stages of their maturation (like plasmablasts), or against molecules involved in B cell activation, represent promising therapeutic targets. A revolution in autoantibody-mediated diseases is pharmacological interference with the neonatal Fc receptor, leading to a rapid reduction of circulating IgGs (including autoantibodies), an approach already suitable for AChR-MG and promising for MuSK-MG. New precision medicine approaches involve Chimeric autoantibody receptor T (CAAR-T) cells that are engineered to target antigen-specific B cells in MuSK-MG and represent a milestone in the development of targeted immunotherapies. This review aims to provide a detailed update on the pathomechanisms involved in MuSK-MG (cellular and humoral aberrations), fostering the understanding of the latest indications regarding the efficacy of different treatment strategies.

IL-6 receptor antibody treatment improves muscle weakness in experimental autoimmune myasthenia gravis mouse model

Non-neuronal cholinergic activity is potentiated in myasthenia gravis

Establishment of Animal Models of Experimental Autoimmune Myositis

Establishment of a Mouse Model of Experimental Autoimmune Myasthenia Gravis

AEB-071 Ameliorates Muscle Weakness by Altering Helper T Lymphocytes in an Experimental Autoimmune Myasthenia Gravis Rat Model

The Effect of CD3-specific Monoclonal Antibody on Treating Experimental Autoimmune Myasthenia Gravis.

Interleukin 10 aggravates experimental autoimmune myasthenia gravis through inducing Th2 and B cell responses to AChR

Mice with IFN-gamma Receptor Deficiency Are Less Susceptible to Experimental Autoimmune Myasthenia Gravis.

Silencing of FCRLB by shRNA ameliorates MuSK-induced EAMG in mice

Increased serum IL-2, IL-4, IL-5 and IL-12p70 levels in AChR subtype generalized myasthenia gravis

Muscle-selective synaptic disassembly and reorganization in MuSK antibody positive MG mice.

Agonist antibody to MuSK protects mice from MuSK myasthenia gravis

Immunotherapies in MuSK-positive Myasthenia Gravis; an IgG4 antibody-mediated disease

The Limitation of IL-10-exposed Dendritic Cells in the Treatment of Experimental Autoimmune Myasthenia Gravis and Myasthenia Gravis

A Targeted Complement Inhibitor CRIg/FH Protects Against Experimental Autoimmune Myasthenia Gravis in Rats Via Immune Modulation

Protective potential of experimental autoimmune myasthenia gravis in Lewis rats by IL-10-modified dendritic cells.

CD20-mediated B cell depletion in acetylcholine receptor autoantibody-positive myasthenia gravis

In vitro modulation of T cells in myasthenia gravis by low-dose IL-2

Astragaloside IV protects against autoimmune myasthenia gravis in rats via regulation of mitophagy and apoptosis

Advances in Immunopathogenesis and Treatment of Myasthenia Gravis

Berberine Attenuates Experimental Autoimmune Myasthenia Gravis Via Rebalancing the T Cell Subsets